NCT03615846Unknown不适用
Comparison of the VerifyNow® Aspirin Test and PRUTest® Platelet Reactivity Tests With Investigational Reagent to Reagents Registered in Japan
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 147
- 试验地点
- 1
- 主要终点
- Naive
研究概览
简要总结
This is a multi-center convenience sample prospective study comparing the results of the Verify Now® Aspirin Test and PRUTest® Platelet Reactivity Tests with the Japan investigational reagents to reagents registered in Japan in the expected population receiving aspirin (ASA) and the P2Y12 inhibitor clopidogrel.
详细描述
- The Primary Objectives of this study are to compare the results of:
- The VerifyNow Aspirin Test with AA, an investigational reagent as defined in Japan, against LTA with AA investigational reagent as defined in Japan (study reference reagent), in subjects receiving DAPT (ASA and clopidogrel or subjects taking no platelet inhibitors including ASA;
- The VerifyNow Aspirin Test with AA, an investigational reagent as defined in Japan, against LTA with collagen (study reference reagent),
o In subjects receiving DAPT (ASA and clopidogrel) or in subjects taking no platelet inhibitors including ASA
- The VerifyNow PRUTest with ADP, an investigational reagent as defined in Japan, and PGE1, against LTA with ADP, an approved reagent in Japan (study reference reagent) and PGE1, and
- The VerifyNow PRUTest with ADP (an investigational reagent as defined in Japan) and PGE1 against LTA with ADP reagent approved in Japan (study reference reagent) with no PGE1, o in up to 75 subjects receiving DAPT (ASA and clopidogrel) and in up to 55 subjects taking no platelet inhibitors (total up to 130 subjects).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females 18 years of age or older.
- •Subjects regularly taking ASA and clopidogrel, for a minimum of 4 days prior to enrollment, or subjects taking no platelet inhibitors including ASA.
- •Willing to participate and able to understand the study, including their rights and any risks associated with their participation, and sign an informed consent.
- •Able and willing to donate a blood sample of 15mL.
- •Exclusion Criteria
- •Enrolled in any other study that involves an investigational drug and/or device.
- •Smoked within one hour before blood draw.
- •Had caffeine within 2 hours before blood draw.
- •Had meals with high fat content within 8 hours before blood draw.
- •A platelet count below 92,000/µL, or above 502,000/µL for VerifyNow Aspirin Test.*
- •A platelet count below 119,000/µL, or above 502,00/µL for VerifyNow PRUTest.*
- •A hematocrit level below 29%, or above 56% for VerifyNow Aspirin Test.*
- •A hematocrit level below 33%, or above 52% for VerifyNow PRUTest.*
- •Within the past 48 hours, exposure to any of the following drugs:
- •Antiplatelet/glycoprotein inhibitors [eptifibatide, tirofiban]
- •Any antiplatelet drug except clopidogrel and ASA [e.g. ticagrelor, prasugrel]
排除标准
- 未提供
结局指标
主要结局
Naive
时间窗: 1 day
Correlation of AggRAM Light Transmittance Aggregometry (LTA) compared to VerifyNow Aspirin Test and VerifyNow PRUTest
VerifyNow® PRUTest
时间窗: 1 day
Correlation of AggRAM Light Transmittance Aggregometry (LTA) compared to VerifyNow PRUTest
VerifyNow® Aspirin Test
时间窗: 1 day
Correlation of AggRAM Light Transmittance Aggregometry (LTA) compared to VerifyNow Aspirin Test
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Appendectomy vs. Symptomatic Treatment in Uncomplicated Acute Appendicitis Among Pediatric PatientsAppendicitisNCT05289713Helsinki University Central Hospital64
已完成
不适用
Comparison of Aneuploidy Risk EvaluationsPregnancyDown SyndromeEdwards SyndromeTurners SyndromePatau SyndromeNCT01663350Verinata Health, Inc.3,000
终止
3 期
Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion SurgeryBlood Loss, SurgicalPostoperative HemorrhageNCT00327379Bayer54
已完成
3 期
Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren'sDupuytren's DiseaseNCT02725528McMaster University22
招募中
不适用
A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot UlcersDiabetic Foot UlcerNCT06618612Organogenesis170